Literature DB >> 618711

A clinical safety trial of stroma-free hemoglobin.

J P Savitsky, J Doczi, J Black, J D Arnold.   

Abstract

A stroma-free hemoglobin (SFH) solution was prepared which was sterile, pyrogen free, and contained only 1.2% of the stromal lipid present in unpurified hemolysate, 250 ml of which was administered slowly intravenously to 8 healthy men. Two control subjects received 250 ml of serum albumin. The SFH infusions were generally well tolerated by 7 of the 8 men. One subject developed abdominal pain and costovertebral angle tenderness after infusion, which disappeared within 48 hr. Bradycardia and a mild increase in blood pressure was present during ths SFH infusions and for 4 to 5 hr thereafter. A decrease in urine output and endogenous creatinine clearance appeared during the SFH infusions and for 2 to 4 hr after infusion. A mild prolongation of the activated partial thromboplastin time developed immediately after infusion. Gross hemoglobinuria appeared as expected during the SFH infusions and completely disappeared by 6 to 10 hr after infusion. All the cardiovascular, renal, and clotting changes were present for only a few hours after the SFH infusion, during the hemoglobinemia (free Hb in plasma). At 24 hr and 7 days after infusion all measurements were normal, and 6 mo follow-up showed no abnormalities or hepatitis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 618711     DOI: 10.1002/cpt197823173

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

1.  Biophysical properties and oxygenation potential of high-molecular-weight glutaraldehyde-polymerized human hemoglobins maintained in the tense and relaxed quaternary states.

Authors:  Ning Zhang; Yiping Jia; Guo Chen; Pedro Cabrales; Andre F Palmer
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

2.  Artificial blood.

Authors:  S J Urbaniak
Journal:  BMJ       Date:  1991-11-30

3.  Washing and filtering of cell-salvaged blood - does it make autotransfusion safer?

Authors:  Gerhardt Konig; Jonathan H Waters
Journal:  Transfus Altern Transfus Med       Date:  2012-12-01

4.  Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin.

Authors:  Peter C Minneci; Katherine J Deans; Huang Zhi; Peter S T Yuen; Robert A Star; Steven M Banks; Alan N Schechter; Charles Natanson; Mark T Gladwin; Steven B Solomon
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

Review 5.  Red cell substitutes: present status.

Authors:  L R Sehgal; H L Sehgal; S A Gould; A L Rosen; R DeWoskin; G S Moss
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

Review 6.  Development of recombinant hemoglobin-based oxygen carriers.

Authors:  Cornelius L Varnado; Todd L Mollan; Ivan Birukou; Bryan J Z Smith; Douglas P Henderson; John S Olson
Journal:  Antioxid Redox Signal       Date:  2012-11-16       Impact factor: 8.401

7.  Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin.

Authors:  Vibhudutta Awasthi; Vivek R Yadav; Beth Goins; William T Phillips
Journal:  J Microencapsul       Date:  2012-12-11       Impact factor: 3.142

Review 8.  Exploring Oxidative Reactions in Hemoglobin Variants Using Mass Spectrometry: Lessons for Engineering Oxidatively Stable Oxygen Therapeutics.

Authors:  Michael Brad Strader; Abdu I Alayash
Journal:  Antioxid Redox Signal       Date:  2016-10-20       Impact factor: 8.401

9.  Hemoglobin infusion does not alter murine pulmonary vascular tone.

Authors:  Arkadi Beloiartsev; David M Baron; Binglan Yu; Kenneth D Bloch; Warren M Zapol
Journal:  Nitric Oxide       Date:  2013-01-08       Impact factor: 4.427

10.  Oxygen delivery during extreme anemia with ultra-pure earthworm hemoglobin.

Authors:  Jacob Elmer; Andre F Palmer; Pedro Cabrales
Journal:  Life Sci       Date:  2012-09-13       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.